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Abstract 
Background: The left atrial appendage (LAA) represents one of the major sources of cardiac thrombus 
formation responsible for TIA/stroke in patients with atrial fibrillation(AF). 
 
Objective: We studied LAA by computed tomography (CT) and by magnetic resonance (MRI) to categorize 
different morphologies and to correlate the morphology with the history of stroke/ transient ischemic attack 
(TIA). 
 
Methods: The study population consisted of 932 patients with drug refractory AF planning to undergo 
transcatheter ablation. All patients underwent cardiac CT or MRI and care was taken to obtain LAA frames. 
All patients were screened for history of TIA/stroke. LAAs were categorized into different morphologies 
which included Cactus, Chicken Wing, Windsock, and Cauliflower. 
 
Results: CT images of 499 patients and MRI images of 433 patients were analyzed (59±10 yrs, 79% male, 
BMI 27±4, EF 60±7, 14% CHADS2 ≥2). The distribution of different LAA morphologies was: Cactus [278 
(30%)], Chicken Wing [451 (48%)], Windsock [179 (19%)], and Cauliflower [24 (3%)]. Out of the 932 
patients, 73 (8%) patients had prior history of ischemic stroke or TIA. The prevalence of pre-procedure 
stroke/TIA in Cactus, Chicken Wing, Windsock, and Cauliflower morphologies were 12%, 4%, 10%, and 
18% respectively (p = 0.003). After controlling for CHADS2 score, gender, and AF types in a multivariable 
logistic model, Chicken Wing morphology was found to be 79% less likely to have a stroke/TIA history (OR 
0.21, 95% CI 0.05-0.91, p=0.036). In separate multivariate model we entered chicken wing as reference 
group and assessed the likelihood of stroke in other groups in relation to reference. Compared to chicken 
wing, Cactus had 4.08 times (p= 0.046), Windsock- 4.5 times (p=0.038), and Cauliflower 8.0 times 
(p=0.056) more likely to have suffered a cerebrovascular ischemic event. The same results were confirmed in 
the subgroup of patients at low thromboembolic risk.  
 
Conclusion: This study suggests that patients with chicken wing LAA morphology are less likely to have an 
embolic event even after controlling for potential confounders. If confirmed, these results could have a 
relevant impact on the anticoagulation management of patients with a low-intermediate risk for stroke/TIA. 
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Introduction 
The left atrial appendage (LAA) represents one of the major sources of cardiac thrombus formation 
responsible for TIA/stroke in patients with atrial fibrillation (AF) (1,2).  Its anatomical structure is 
challenging (3). Embriologically it is a remnant of the primordial left atrium. It lies anteriorly in the 
atrioventricular sulcus in close proximity to the left circumflex artery, the left phrenic nerve and the 
left pulmonary veins (3,4,5). 
The shape of the LAA is variable. Several studies have described the LAA as a long tubular and 
hooked structure with different lobes. The imaging of the different structures and lobes is of utmost 
importance to diagnose the presence of LAA thrombus especially in patients with non-valvular AF 
(3,6,7,8). 
The widespread utilization of left atrium ablation procedures and the presence of LAA occlusion 
devices for the treatment of patients with AF has increased the interest for this structure (9,10,11). 
Multidetector computerized tomography (CT) and magnetic resonance imaging (MRI), are well 
known imaging techniques able to detect high quality images of the LAA (12,13). 
We quantitatively studied various morphologic parameters of the left atrial appendage (LAA) by 
computed tomography (CT) and by magnetic resonance (MRI) to categorize different LAA 
morphologies, and tried to correlate the different morphologies with the patient history of 
stroke/TIA. 
 
Methods 
Patient population 
The study population consisted of 932 patients with drug refractory AF planning to undergo 
transcatheter ablation. All patients underwent cardiac CT or MRI and care was taken to obtain LAA 
frames. All patients were screened for previous history of TIA/stroke. CHADS2 score was obtained 
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in all patients.  LAAs were categorized into different morphologies by CT scan and MRI which 
included Cactus, Chicken Wing, Windsock, and Cauliflower (see below and Table 1). 
Echocardiograhy TT/TE parameters 
 
CT 
Cardiac CT imaging of the LAA was performed as previously described (3). Briefly, patients were 
scanned with contrast-enhanced ECG gated CT scan (Lightspeed Ultra, GE Healthcare, VA, USA). 
The slice acquisition thickness ranged from 0.625 to 1.25 mm. Three-dimension structures of the 
left atrium and LAA, were constructed using the volume rendered postprocessing technique. 
Standard measurements of LAA volume, velocity, and diameters were obtained. The morphology of 
the LAA was also evaluated using multiplanar reconstruction. LAA morphologies were classified 
by two expert cardiac CT radiologists, who were blinded to the clinical data and history of previous 
stroke/TIA. 
 
MRI 
Contrast-enhanced magnetic resonance imaging of the left atrium was performed by intravenous 
administration of 0.2 mmol/Kg of contrast agent (Gadobutrolo, GADOVIST®, Bayer S.P.A., Berlin, 
Germany), followed by a bolus of 20 mL of physiological solution. Images were obtained with a 
body-array coil 1.5 Tesla magnetic resonance imaging system (Magneton Avanto® 1.5T, Siemens, 
Erlangen, Germany). Three dimensional (3D) magnetic resonance angiography (MRA) was 
obtained with a breath-hold 3D fast-field Spoiled Gradient Echo (SPGR) imaging sequence 
performed in sagittal, coronal and axial views to obtain an anatomical view of the entire thorax. A 
narrow bandwidth of 31.25 kHz was used to reduce noise and improve the signal-to-noise ratio. The 
fractional echos (echo time of 1.08 ms) were used to provide T1-weighting and minimize flow 
artifacts and a flip angle of 20° was chosen to enhance background suppression. The final 3D 
volume was acquired as a coronal slab (typical field-of-view 40 cm, range 36-44 cm), using a 
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rectangular field-of-view to decrease the acquisition time of the sequence. The bolus tracking 
technique (CARE-bolus) guaranteed the highest left atrium signal intensity by starting a multiphase 
SPGR image series in a coronal view at the exact time during which the bolus passed through the 
left ventricle-aortic root. 
In order to keep speed magnetization in steady-state during the acquisition (repetition time 2.84 
ms), contrast-enhanced MRA measurements were not ECG-gated. Another reason not to use gating 
was that entire measurement time had to be minimized to follow the bolus of the contrast agent. 
Motion artifacts from breathing were eliminated by patient’s breath-hold for the time of the 
sequence (below 15 sec). Standard measurements of LAA volume and diameters were obtained 
following volume rendering and integration in the Polaris image processing package of the Carto-
Merge system (Biosense Webster, Diamond. Bar, California, USA). LAA morphologies were 
determined by two expert cardiac MRI radiologists, who were blinded to the clinical data and 
history of previous stroke/TIA. 
 
Classification of LAA Morphology 
Based on its morphologies, the LAA was classified as: 
(1) The Cactus LAA, with a dominant central lobe with secondary lobes extending from the central 
lobe in both superior and inferior directions (Figure 1). 
(2) The Chicken Wing LAA, with an obvious bend in the proximal or middle part of the dominant 
lobe, or folding back of the LAA anatomy on itself at some distance from the perceived LAA 
ostium. This type of LAA may have secondary lobes or twigs (Figure 2). 
 (3) The WindSock LAA, with 1 dominant lobe of sufficient length as the primary structure. 
Variations of this LAA type arise with the location and number of secondary or even tertiary lobes 
arising from the dominant lobe (Figure 3). 
8 
 
(4) The Cauliflower LAA, with limited overall length with more complex internal characteristics. 
Variations of this LAA type have a more irregular shape of the LAA ostium (oval vs. round), a 
variable number of lobes with lack of a dominant lobe (Figure 4). 
 
 
 
Statistical analysis 
All continuous data are presented as mean ± standard deviation and were compared using analysis 
of variance (ANOVA) or Kruskal-Wallis test where appropriate. Categorical variables are described 
as count and percent and compared by using Pearson's chi-square or Fisher’s exact test. Since 
classification into different LAA categories was determined by different operators using CT and 
MRI, we tested inter-operator concordance. Cohen's Kappa was utilized to assess estimate inter-
rater agreement. Multivariable logistic model was used for identifying significant predictors of 
stroke/TIA. All potential confounders were entered into the model based on known clinical 
relevance, or significant association observed in univariate analysis. The controlling variables used 
in the model were- age, gender, hypertension, diabetes, AF types, and CHADS2 score. Based on the 
components of the CHADS2 score, except the history of previous stroke/TIA, the study population 
was stratified into two sub-groups with low and intermediate/high risk of thromboembolisms 
(CHAD 0-1 and ≥2) and a sub-analysis was performed to investigate the possible association of 
LAA types with stroke/TIA within each group. The odds ratio (OR) and 95% confidence interval 
(CI) of stroke/TIA were computed. All tests were two-sided and a P-value <0.05 was considered 
statistically significant. Analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC, 
USA). 
 
Results 
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CT images of 499 patients and MRI images of 433 patients (59±10 yrs, 79% male, BMI 27±4 
Kg/m2, EF 60±7%, 14% CHADS2 ≥2) presenting for catheter ablation of AF were prospectively 
collected. The distribution of LAA morphologies was: Cactus [278 (30%)], Chicken Wing [451 
(48%)], Windsock [179 (19%)] and Cauliflower [24 (3%)]. No statistically significant bias was 
noted in classifying LAA morphology by operators using CT and MRI (Kappa = 0.67; 95% CI 
0.48-0.87, p = 0.001). 
Table 1 presents the baseline demographic, clinical characteristics, and LAA measurements for the 
4 LAA types. No differences were found in the incidence of congestive heart failure, hypertension, 
diabetes, dyslipidemia, or coronary artery disease. The groups were different with respect to gender, 
history of stroke/TIA, and CHADS2 score of ≥2. The windsock type was more likely to be male. In 
addition, compared to other groups, Chicken Wing was the most prevalent LAA morphology 
(48%), had the lowest prevalence of prior stroke/TIA (4%), and CHADS2 ≥2 (9%). No difference 
was noted for left atrium diameter, left ventricular ejection fraction (LVEF). 
 
Prevalence of pre-procedure stroke/TIA: 
In the study cohort, 78 (8%) of the 932 patients had a history of stroke/TIA prior to AF ablation. 
The distribution of the event (stroke/TIA) was significantly different across the LAA types [Cactus, 
Chicken Wing, Windsock, and Cauliflower were 35 (12%), 20 (4%), 19 (10%), and 4 (18%) 
respectively (p <0.001)]. 
Table 2 compares the clinical characteristics of patients with and without stroke/TIA history. The 
Cactus type was significantly more likely to have had a stroke (44% with-stroke had cactus type 
whereas 28% of stroke-free had cactus morphology, p = 0.002). On the other hand, Chicken Wing 
was strongly associated with absence of history of stroke (p < 0.001). As expected, a difference in 
CHADS2 scores was found to be significant between stroke and no history of stroke (table 2). 
 
Univariable Analysis 
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As revealed from univariable analysis, patients with history of stroke/TIA were more likely to have 
cactus type LAA [odds ratio (OR) 2.5, 95% CI 1.02 to 6.08, p=0.045], and CHADS2 score ≥2 (OR 
24, 95% CI 9.93 to 60.8, p<0.001), and those with Chicken Wing morphology were significantly 
less likely to have had stroke/TIA (OR 0.18, 95% CI 0.04 to 0.77, p= 0.021). The OR and 95% CI 
for baseline risk factors are shown in table 3. 
Multivariable Analysis 
After controlling for CHADS2 score, gender, and AF types in a multivariable logistic model, 
Chicken Wing was found to be 79% less likely to have a stroke/TIA history (OR 0.21, 95% CI 
0.05-0.91, p=0.036). In separate multivariate model we entered Chicken Wing as reference group 
and assessed the likelihood of stroke/TIA in other groups in relation to reference. Compared to 
Chicken Wing, Cactus had 4 times (OR 4.08, 95% CI 1.04 to 17.27, p= 0.046), Windsock 5 times 
(OR 4.8, 95% CI 1.89 to 22.50, p=0.038), and Cauliflower 8 times (OR 8.02, 95% CI 0.92 to 27.86, 
p=0.056) more likely to have a stroke/TIA history. Overall, the odds ratio for stroke/TIA in non-
Chicken Wing LAA morphology was 2.95 (95% CI 1.75-4.99, p=0.041) compared to Chicken 
Wing. 
LAA morphology and risk of stroke/TIA in low-risk patients 
Also among patients with CHAD 0-1, Chicken Wing LAA had the lowest risk of previous 
stroke/TIA. Indeed, stroke was significantly more prevalent in non-Chicken Wing morphology 
compared to the Chicken Wing category (4.6% vs. 0.7%, p=0.001). After adjusting for gender, AF 
type, and LA size, Chicken Wing morphology was found to be an independent predictor of stroke 
(OR 10.1, 95% CI 1.25 to 79.7, p=0.019).  
 
Discussion 
 
This is the first paper correlating different LAA morphologies as obtained with CT and or MRI 
images with the presence of TIA/stroke. 
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We found that patients with the Chicken Wing LAA morphology have a statistically significant 
lower risk of previous stroke/TIA when compared to all the remaining LAA morphology described. 
The Chicken Wing LAA morphology was the most prevalent one (48% of our population), and the 
least associated with history of stroke/TIA. 
These results are novel and could be clinically relevant, especially for patients currently judged at 
low risk of thromboembolic events, such as those with CHAD scores of 0 and 1. In these patients, 
the presence of a non-Chicken Wing LAA morphology strikingly increases the risk of 
thromboembolic events (up to 4.6%, corresponding to a 10-fold increased risk of stroke/TIA), 
which suggest the appropriateness of a more aggressive antithrombotic therapy. 
Further, this study may provide insights into why stroke/TIA has been described also in patients 
with a theoretical low risk of thromboembolsims (CHAD score of zero). 
The physician and the technician acquiring the CT and the MRI images were blinded to the 
patient’s history, which minimize the risk of bias; in addition, all the statistical analyses were 
corrected for all possible confounders, and demonstrated no interaction between the CHADS2 score 
and the risk of stroke/TIA linked to different LAA morphologies. 
Anatomical and Mechanical Concepts  
The LAA is an embryological remnant that functions during conditions of fluid overload as 
reservoir (6). Due to its hooked morphology, the LAA is prone to stasis and for this reason, 
represents the prevalent site of thrombus formation in patients with AF (6). Several variables have 
been described to be associated with thrombus formation. 
Leung et al and Manning et al. (1-7) with trans-esophageal evaluations reported that up to 98% of 
atrial thrombi occurring during AF derive from the LAA. 
The LAA size is associated with increased thromboembolic risk (14). Autopsy studies have reported 
a direct association between the LAA size and the risk for stroke/TIA especially in patients with 
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non valvular AF (15,16). In our study, no significant correlation between LAA size and the risk of 
stroke/TIA was found (Table 2). 
To date, there is no data correlating the various LAA morphologies with the thromboembolic risk of 
stroke/TIA in patients with AF. 
Anticoagulation Management 
The CHADS2 score was introduced into guidelines and implemented into clinical practice to assess 
individual thromboembolic risk in patients with AF. In patients with CHADS2 score more than 1 
the need for oral anticoagulation is not questionable, but in patients with low-intermediate risk for 
stroke (CHADS2 score = 1) no consensus exist on whether patients should receive oral 
anticoagulation or antiplatelet therapy (17,18). Recently with the aim to reduce the risk for stroke in 
patients with AF and identifying a higher number of patients at risk, a new score has been proposed 
by the European guidelines: the CHA2DS2-VaSc score (19). Although with this new score a higher 
number of patients are required to use oral anticoagulation, the clinical decision making is still 
controversial in patients with low-risk CHA2DS2-VaSc score; the implementation of LAA 
morphology may aid the clinical decision toward oral anticoagulant or antiplatelet therapy. 
Importantly, it should not be forgotten that the risk for stroke should be balanced with the risk for 
bleeding, which is another dramatic complication is patients with AF treated with anticoagulants.  
In patients with contraindication to Warfarin or due to physician e/o patient’s preference it is 
possible to use antiplatelet therapy although with contrasting results (17,18,19). 
In this scenario the identification of an appendage morphology associated with a lower risk for 
stroke may further guide the clinicians in the decision process. 
The present study suggests that the LAA morphology should be taken into account when planning 
the anticoagulation management of patient with AF. The LAA morphology remained the most 
powerful independent predictor of stroke/TIA also after adjustment for the CHADS2 score at 
multivariable regression analysis, which further strengthens the relevance of our findings. Of note, 
LAA morphology was confirmed a powerful predictor of thromboembolic events also in the 
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subgroup of patients with a low-intermediate baseline risk of stroke/TIA, such as those with 
CHADS2 scores of 0 to 1. 
The advent of the new oral anticoagulants with improved thromboembolic protection, lower risk of 
bleeding, and better patient compliance, may justify the appropriateness of early antithrombotic 
therapy in patients at lower risk of thromboembolic events and non-Chicken Wing LAA 
morphology (20,21,22). The cost-effectiveness of such anticoagulation management when 
compared to warfarin will need further investigation.  
 
 
 
Study Limitation 
Although retrospective, this study included a large sample size. We could not be able to retrieve 
drug treatment, and specifically the antiaggregation/anticoagulation status at the time of the event, 
which may potentially affect the results in patients at high risk of stroke (i.e., CHADS2 scores ≥2). 
Although this might be considered a major limitation, the strong independent statistical association 
between LAA morphology and risk of stroke is of utmost clinical relevance. 
 
Conclusion 
 
This study suggests that patients with non-Chicken Wing LAA morphology are significantly more 
likely to have an embolic event, even after controlling for potential confounders. If confirmed, these 
results could have a relevant impact on the anticoagulation management of patients with AF, 
especially of those with an intermediate-low risk for stroke (i.e., CHADS2 score 0 to 1) in whom 
oral anticoagulant therapy is currently not recommended. 
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Table 1: Baseline Characteristics 
 
  
Overall 
Population 
Type 1 
(Cactus) 
Type 2 
(Chicken 
Wing) 
Type 3 
(Windsock) 
Type 4 
(Cauliflower) P value  
 
Groups with 
pair-wise 
significant 
difference 
N=932 932 278 451 179 24     
Age, yrs 59±10 59±09 57±11 59±10 62±15 0.097   
Male 734(79%) 218(78%) 356(79%) 147(82%) 13(55%) 0.019 4 vs. 3; 4 vs. 2 
AF Type               
    PAF 548(59%) 167(60%) 266(59%) 100(56%) 15(64%) 0.810   
    PER 336(36%) 89(32%) 167(37%) 73(41%) 7(28%) 0.235   
    LSP 48(5%) 22(8%) 18(4%) 6(3%) 2(8%) 0.086   
AF Duration, months 59±65 67±77 30±41 50±62 47±46 0.404   
BMI 27±04 27±04 27±04 27±03 26±03 0.906   
Dyslipidemia 218(23%) 68(25%) 99(22%) 47(27%) 4(18%) 0.565   
Hypertension 450(48%) 143(52%) 201(45%) 95(53%) 11(45%) 0.150   
CHF 42(5%) 9(3%) 19(4%) 13(7%) 1(4%) 0.212   
Diabetes 40(4%) 19(7%) 13(3%) 6(4%) 2(9%) 0.547   
Prior stroke/TIA 78(8%) 35(12%) 20(4%) 19(10%) 4(18%) <0.001 2 vs. 1; 2 vs. 3 
CAD 45(5%) 15(5%) 24(5%) 4(2%) 2(9%) 0.643   
CHADS2 0 428(46%) 115(42%) 237(53%) 67(37%) 8(33%) <0.001 2 vs. 3; 2 vs. 1 
CHADS2- 1 377(40%) 111(40%) 173(38%) 84(47%) 9(36%) 0.258   
CHADS2 ≥2 127(14%) 52(19%) 41(9%) 28(16%) 7(27%) <0.001 2 vs. 1; 2 vs. 4 
LV EF, % 60±07 60±08 59±07 60±07 60±02 0.895   
LAA volume 14.26±06.17 14.63±07.58 // 14.98±06.71 // 0.781   
LAA Velocity, mm 74.54±25.43 69.45±28.43 77.34±26.34 79.04±29.84 78.00±18.39 0.257   
LAA AP Diameter, mm 45.36±06.77 46.07±05.90 44.33±06.95 46.68±06.76 42.50±06.66 0.029   
LAA Longitudinal Diameter 60.70±07.83 62.07±08.05 58.49±07.99 61.55±07.94 56.50±07.92 0.067   
LAA Lat-Median Diameter 46.24±07.59 47.05±08.30 45.61±07.29 47.50±07.67 43.67±04.03 0.192   
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Table 2: Baseline characteristics according to event (Stroke/TIA) 
 
  
No History of 
Stroke/TIA (n-854) 
Prior Stroke/TIA 
(n=78) 
P 
value  
N=932 854 78   
Age, yrs 58±10 62±8 0.304 
Male 674(79%) 60(76%) 0.679 
LAA Type       
    Cactus 243(28%) 35(44%) 0.002 
    Chicken Wing 431(50%) 20(26%) <0.001 
    Windsock 160(19%) 19(24%) 0.228 
    Cauliflower 20(2%) 4(5%) 0.137 
BMI 27±04 27±04 0.908 
Dyslipidemia 193(23%) 25(32%) 0.059 
Hypertension 409(48%) 41(53%) 0.429 
CHF 39(5%) 3(4%) 0.769 
Diabetes 35(4%) 5(6%) 0.335 
CAD 43(5%) 2(3%) 0.330 
CHADS2= 0-1 783(92%) 21(27%) <0.001 
CHADS2 ≥2 71 (8%) 57(73%) <0.001 
LV EF, % 58±08 60±07 0.140 
LAA volume 14.13±06.04 15.04±07.10 0.372 
LAA Velocity, mm 74.77±25.93 72.26±20.23 0.220 
LAA AP Diameter, mm 45.36±06.76 45.40±06.90 0.822 
LAA Longitudinal Diameter, mm 60.64±07.97 61.54±05.83 0.062 
LAA Lat-Median Diameter, mm 46.27±07.49 45.81±08.81 0.216 
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Table 3: Univariate Odds Ratio for stroke/TIA. 
 
Variable Odds Ratio 95% CI p value 
Age, yrs 1.04(1.00-1.09) 0.045 
Gender (Male) 1.17(0.51-2.68) 0.708 
LAA Type 
 
0.000 
    Cactus 2.50(1.02-6.08) 0.045 
    Chicken Wing 0.18(0.04-0.77) 0.021 
    Windsock 1.13(0.40-3.17) 0.821 
    Cauliflower 1.99(0.23-17.23) 0.534 
CHADS2 ≥2 24.48(0.93-60.84) <0.001 
BMI 1.03(0.94-1.13) 0.562 
Dyslipidemia 1.60(0.75-3.40) 0.225 
Hypertension 1.23(0.61-2.47) 0.571 
Diabetes 1.40(0.31-6.35) 0.659 
LV EF, % 0.95(0.91-1.00) 0.050 
ARB 1.17(0.46-2.93) 0.746 
ACE Inhibitor 2.00(0.89-4.48) 0.094 
Beta-blocker 0.72(0.33-1.59) 0.415 
Aspirin/Plavix 0.30(0.07-1.28) 0.103 
Lipid-lowering therapy 2.08(0.68-6.40) 0.200 
LAA volume 1.02(0.94-1.11) 0.609 
LAA Velocity, mm 1.00(0.98-1.02) 0.681 
LAA AP Diameter, mm 1.00(0.95-1.06) 0.975 
LAA Longitudinal Diameter 1.02(0.96-1.07) 0.571 
LAA Lat-Median Diameter 0.99(0.94-1.05) 0.763 
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Figure legend 
 
 
Figure 1: A CT scan and B MRI of a Cactus LAA morphology 
 
Figure 2: A-B CT scan and C MRI of a Chicken Wing LAA morphology 
 
Figure 3: A-B CT scan and C MRI of a Windsock LAA morphology 
 
Figure 4: A CT scan and B MRI of a Cauliflower  LAA morphology 
 
Figure 5: Rate of stroke/TIA across Chicken Wing and non-Chicken Wing morphologies in 
patients with low thromboembolic risk (CHAD score 0-1). Non-Chicken Wing LAA morphology 
increases the risk of stroke/TIA more than 6-fold compared to Chicken Wing. 
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